TRACON Pharmaceuticals Inc (NASDAQ:TCON)

1.51
Delayed Data
As of Nov 23
 0.00 / 0.00%
Today’s Change
1.24
Today|||52-Week Range
3.79
-45.49%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$33.5M

Company Description

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Contact Information

TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive
San Diego California 92122-1243
P:(858) 550-0780
Investor Relations:

Employees

Shareholders

Individual stakeholders42.46%
Other institutional38.84%
Mutual fund holders3.66%

Top Executives

Charles P. TheuerPresident, Chief Executive Officer & Director
Scott B. BrownChief Financial Officer
Bonne J. AdamsExecutive Vice President-Clinical Operations
James L. FreddoChief Medical Officer
Brenda MarcziSenior Vice President-Regulatory Affairs